Human neural progenitor cells (hNPC) can deliver neuroprotective
molecules to sites of neurodegeneration and show great promise for neurodegenerative disease therapy. However, ex vivo gene therapy
strategies raise significant safety issues associated with unanticipated adverse reactions. We are investigating the potential of
gene-directed enzyme prodrug therapy (GDEPT) as a method for treating such adverse reactions. In the experiments presented, we
assessed hNPC viability using the CellTiter-Glo® Luminescent Cell Viability and CellTiter 96® AQueous One Solution Cell
Proliferation Assays. The enhanced sensitivity provided by the CellTiter-Glo® Assay allowed us to evaluate the effectiveness of GDEPT
strategies on hNPC.
Cell Notes 20, 6–8.
Elizabeth E. Capowski and Clive N. Svendsen